» Articles » PMID: 36483550

Identification of Immune-related Features Involved in Duchenne Muscular Dystrophy: A Bidirectional Transcriptome and Proteome-driven Analysis

Overview
Journal Front Immunol
Date 2022 Dec 9
PMID 36483550
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We aimed to investigate the biological mechanism and feature genes of Duchenne muscular dystrophy (DMD) by multi-omics and experimental verification strategy.

Methods: We integrated the transcriptomic and proteomic methods to find the differentially expressed mRNAs (DEMs) and proteins (DEPs) between DMD and Control groups. Weighted gene co-expression network analysis (WGCNA) was then used to identify modules of highly correlated genes and hub genes. In the following steps, the immune and stromal cells infiltrations were accomplished by xCELL algorithm. Furthermore, TF and miRNA prediction were performed with Networkanalyst. ELISA, western blot and external datasets were performed to verify the key proteins/mRNAs in DMD patient and mouse. Finally, a nomogram model was established based on the potential biomarkers.

Results: 4515 DEMs and 56 DEPs were obtained from the transcriptomic and proteomic study respectively. 14 common genes were identified, which is enriched in muscle contraction and inflammation-related pathways. Meanwhile, we observed 33 significant differences in the infiltration of cells in DMD. Afterwards, a total of 22 miRNAs and 23 TF genes interacted with the common genes, including TFAP2C, MAX, MYC, NFKB1, RELA, hsa-miR-1255a, hsa-miR-130a, hsa-miR-130b, hsa-miR-152, and hsa-miR-17. In addition, three genes (ATP6AP2, CTSS, and VIM) showed excellent diagnostic performance on discriminating DMD in GSE1004, GSE3307, GSE6011 and GSE38417 datasets (all AUC > 0.8), which is validated in patients (10 DMD vs. 10 controls), DMD with exon 55 mutations, mdx mouse, and nomogram model.

Conclusion: Taken together, ATP6AP2, CTSS, and VIM play important roles in the inflammatory response in DMD, which may serve as diagnostic biomarkers and therapeutic targets.

Citing Articles

Exploring novel natural compound-based therapies for Duchenne muscular dystrophy management: insights from network pharmacology, QSAR modeling, molecular dynamics, and free energy calculations.

Saeed M, Haque A, Shoaib A, Danish Rizvi S Front Pharmacol. 2024; 15:1395014.

PMID: 39415830 PMC: 11481126. DOI: 10.3389/fphar.2024.1395014.


How Can Proteomics Help to Elucidate the Pathophysiological Crosstalk in Muscular Dystrophy and Associated Multi-System Dysfunction?.

Dowling P, Trollet C, Negroni E, Swandulla D, Ohlendieck K Proteomes. 2024; 12(1).

PMID: 38250815 PMC: 10801633. DOI: 10.3390/proteomes12010004.


Transcriptomic analysis of paired healthy human skeletal muscles to identify modulators of disease severity in DMD.

Nieves-Rodriguez S, Barthelemy F, Woods J, Douine E, Wang R, Scripture-Adams D Front Genet. 2023; 14:1216066.

PMID: 37576554 PMC: 10415210. DOI: 10.3389/fgene.2023.1216066.


Effect of ketogenic diet on exercise tolerance and transcriptome of gastrocnemius in mice.

Zhang J, Chen B, Zou K Open Life Sci. 2023; 18(1):20220570.

PMID: 36852401 PMC: 9961969. DOI: 10.1515/biol-2022-0570.

References
1.
Sun C, Shen L, Zhang Z, Xie X . Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update. Genes (Basel). 2020; 11(8). PMC: 7463903. DOI: 10.3390/genes11080837. View

2.
Zhou Y, Chen L, Zhang Y, Hu S, Dong Z, Wu M . Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer. Mol Med. 2019; 25(1):47. PMC: 6842480. DOI: 10.1186/s10020-019-0113-2. View

3.
Estrellas K, Chung L, Cheu L, Sadtler K, Majumdar S, Mula J . Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy. J Biol Chem. 2018; 293(40):15594-15605. PMC: 6177591. DOI: 10.1074/jbc.RA118.004417. View

4.
Bhattarai S, Li Q, Ding J, Liang F, Gusev E, Lapohos O . TLR4 is a regulator of trained immunity in a murine model of Duchenne muscular dystrophy. Nat Commun. 2022; 13(1):879. PMC: 8847425. DOI: 10.1038/s41467-022-28531-1. View

5.
Cordova G, Negroni E, Cabello-Verrugio C, Mouly V, Trollet C . Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. Front Genet. 2018; 9:114. PMC: 5902687. DOI: 10.3389/fgene.2018.00114. View